CN111217893A - Black fungus agglutinin and preparation method thereof - Google Patents
Black fungus agglutinin and preparation method thereof Download PDFInfo
- Publication number
- CN111217893A CN111217893A CN202010031547.3A CN202010031547A CN111217893A CN 111217893 A CN111217893 A CN 111217893A CN 202010031547 A CN202010031547 A CN 202010031547A CN 111217893 A CN111217893 A CN 111217893A
- Authority
- CN
- China
- Prior art keywords
- laa
- lectin
- agglutinin
- solution
- black fungus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710186708 Agglutinin Proteins 0.000 title claims abstract description 23
- 101710146024 Horcolin Proteins 0.000 title claims abstract description 23
- 101710189395 Lectin Proteins 0.000 title claims abstract description 23
- 101710179758 Mannose-specific lectin Proteins 0.000 title claims abstract description 23
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 title claims abstract description 23
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 title claims abstract description 23
- 239000000910 agglutinin Substances 0.000 title claims abstract description 23
- 241000233866 Fungi Species 0.000 title claims description 48
- 238000002360 preparation method Methods 0.000 title claims description 5
- 235000000023 Auricularia auricula Nutrition 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 16
- 102000009338 Gastric Mucins Human genes 0.000 claims abstract description 12
- 108010009066 Gastric Mucins Proteins 0.000 claims abstract description 12
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 claims abstract description 12
- 239000011543 agarose gel Substances 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 7
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 241001149430 Auricularia auricula-judae Species 0.000 claims abstract 7
- 239000002523 lectin Substances 0.000 claims description 77
- 108090001090 Lectins Proteins 0.000 claims description 76
- 102000004856 Lectins Human genes 0.000 claims description 76
- 239000000243 solution Substances 0.000 claims description 48
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 17
- 238000000108 ultra-filtration Methods 0.000 claims description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000287 crude extract Substances 0.000 claims description 13
- 239000004471 Glycine Substances 0.000 claims description 12
- 239000007853 buffer solution Substances 0.000 claims description 12
- 239000011550 stock solution Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 241000221377 Auricularia Species 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000005360 mashing Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 238000010612 desalination reaction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 229920002684 Sepharose Polymers 0.000 claims 3
- 238000005119 centrifugation Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 69
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 abstract description 14
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract description 11
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract description 11
- 210000002540 macrophage Anatomy 0.000 abstract description 11
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000005907 cancer growth Effects 0.000 abstract description 2
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 244000028550 Auricularia auricula Species 0.000 description 87
- 230000003078 antioxidant effect Effects 0.000 description 17
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 17
- 239000002158 endotoxin Substances 0.000 description 17
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000003963 antioxidant agent Substances 0.000 description 16
- 230000005764 inhibitory process Effects 0.000 description 16
- 229920006008 lipopolysaccharide Polymers 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 9
- 230000031700 light absorption Effects 0.000 description 9
- 230000009471 action Effects 0.000 description 8
- 229940079877 pyrogallol Drugs 0.000 description 8
- -1 superoxide anions Chemical class 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 6
- 239000012488 sample solution Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000012086 standard solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 101710183568 Serine/threonine-protein kinase PknK Proteins 0.000 description 4
- 238000006701 autoxidation reaction Methods 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010046016 Peanut Agglutinin Proteins 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 150000008049 diazo compounds Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 235000003891 ferrous sulphate Nutrition 0.000 description 2
- 239000011790 ferrous sulphate Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000012599 radical scavenging assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 108010048090 soybean lectin Proteins 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229950000244 sulfanilic acid Drugs 0.000 description 2
- ZCUQOPGIJRGJDA-UHFFFAOYSA-N 1-naphthalen-1-ylethane-1,2-diamine Chemical compound C1=CC=C2C(C(N)CN)=CC=CC2=C1 ZCUQOPGIJRGJDA-UHFFFAOYSA-N 0.000 description 1
- UZEFHQIOSJWWSB-UHFFFAOYSA-N 4-azidobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(N=[N+]=[N-])C=C1 UZEFHQIOSJWWSB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 229940123541 Lectin inhibitor Drugs 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- WZRRZVUZWWMSKH-UHFFFAOYSA-N n'-naphthalen-1-ylethane-1,2-diamine;hydrochloride Chemical compound Cl.C1=CC=C2C(NCCN)=CC=CC2=C1 WZRRZVUZWWMSKH-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
- C07K14/375—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from Basidiomycetes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
An auricularia auricula agglutinin and its preparing process, wherein the auricularia auricula agglutinin is prepared through preparing the coarse extract of auricularia auricula agglutinin, mixing it with the pig's gastric mucin II-cyanogen bromide activated agarose gel, centrifugal dissociation, ultrafiltering, freeze drying to obtain auricularia auricula agglutinin LAA, and features suppressing the growth of cancer cells, promoting the release of NO from macrophage, IL-1 β and TNF- α, and improving immunity.
Description
Technical Field
The invention relates to a lectin and a preparation method thereof.
Background
Lectin (Lectin) refers to a glycoprotein or sugar-binding protein purified from various plants, invertebrates and higher animals, and is called Lectin because it can agglutinate red blood cells (including blood group substances). Phytoagglutinin (PNA) is commonly used, and is generally named after the plant from which it is extracted, such as concanavalin a (ConA), Wheat Germ Agglutinin (WGA), Peanut agglutinin (PNA), Soybean agglutinin (SBA), and the like, and the agglutinin is a generic name thereof.
Lectins are proteins capable of binding to sugars, which are synthesized and secreted by both animal and plant cells, and play an important role in cell recognition and adhesion reactions, mainly to promote intercellular adhesion. Lectins have more than one site for binding to sugars and are therefore involved in cell recognition and adhesion, linking different cells.
Disclosure of Invention
The invention provides a black fungus lectin and a preparation method thereof.
The black fungus agglutinin is prepared by the following steps:
firstly, preparing a black fungus lectin crude extract;
secondly, mixing the black fungus agglutinin crude extract with pig gastric mucin II type-cyanogen bromide activated agarose gel;
and thirdly, centrifuging, dissociating, ultrafiltering, and freeze-drying to obtain the auricularia auricula lectin LAA.
The auricularia auricula lectin LAA is prepared by the method.
The relative molecular mass of the auricularia auricula agglutinin LAA is determined to be 18913.22 by MALDI-TOF/TOF; the sequence of the N-terminal of the black fungus agglutinin LAA is detected to be ITAPTTTSSAATE; the black fungus agglutinin LAA is analyzed to contain the following 4 peptide segments by protein identification and comparison with a UniProt database: QIDAERK, TNHSVVVTNDK, RLNFTAGNPFPR, VRELEQVDSMTK. The existence of the same sequence is not found in the existing black fungus protein mass spectrum library, so that the black fungus lectin LAA is deduced to be a novel protein in black fungus and is determined to be a novel lectin.
The black fungus lectin can inhibit the growth of cancer cells, promote macrophages to release NO, IL-1 β and TNF- α, and has the activity of improving immunity.
The black fungus agglutinin of the invention can eliminate ABTS free radical (ABTS)+) Hydroxyl radical (. OH) and superoxide anion (. O)2 -) Has excellent antioxidant effect.
The black fungus agglutinin of the invention has no toxicity to macrophage RAW 264.7.
Drawings
FIG. 1 is a 200-fold observation chart of Auricularia auricular lectin LAA for inhibiting proliferation of lung cancer cell A549; FIG. 1A: negative control; FIG. 1B: the LAA concentration is 50 mug/mL; FIG. 1C: the LAA concentration is 100 mug/mL; FIG. 1D: the LAA concentration is 150 mug/mL; FIG. 1E: the LAA concentration is 200 mug/mL; FIG. 1F: the LAA concentration was 250. mu.g/mL.
FIG. 2 is a graph showing the inhibition of A549 cells by auricularia auricula lectin LAA.
FIG. 3 is a 200-fold observation chart of Auricularia auricula lectin LAA for inhibiting proliferation of cancer cell MCF-7; FIG. 3A: negative control; FIG. 3B: the LAA concentration is 50 mug/mL; FIG. 3C: the LAA concentration is 100 mug/mL; FIG. 3D: the LAA concentration is 150 mug/mL; FIG. 3E: the LAA concentration is 200 mug/mL; FIG. 3F: the LAA concentration was 250. mu.g/mL.
FIG. 4 is a graph showing the inhibition of MCF-7 cells by auricularia auricula-judae lectin LAA.
FIG. 5 is a 200-fold observation chart of Auricularia auricula lectin LAA inhibiting cancer cell SGC-7901 proliferation; FIG. 5A: negative control; FIG. 5B: the LAA concentration is 50 mug/mL; FIG. 5C: the LAA concentration is 100 mug/mL; FIG. 5D: the LAA concentration is 150 mug/mL; FIG. 5E: the LAA concentration is 200 mug/mL; FIG. 5F: the LAA concentration was 250. mu.g/mL.
FIG. 6 is a graph showing the inhibition of SGC-7901 cells by auricularia auricula lectin LAA.
FIG. 7 is a 200-fold observation chart of Auricularia auricula lectin LAA for inhibiting the proliferation of cancer cell HepG-2; FIG. 7A: negative control; FIG. 7B: the LAA concentration is 50 mug/mL; FIG. 7C: the LAA concentration is 100 mug/mL; FIG. 7D: the LAA concentration is 150 mug/mL; FIG. 7E: the LAA concentration is 200 mug/mL; FIG. 7F: the LAA concentration was 250. mu.g/mL.
FIG. 8 is a graph showing the inhibition of HepG-2 cells by the auricularia auricula-judae lectin LAA.
Fig. 9 is a graph of auricularia auricula lectin LAA as a function of NO release, (n ═ 3),. p <0.05,. p <0.01,. p < 0.001.
Fig. 10 is a purity measurement chart of auricularia auricula lectin LAA, (n ═ 3),. p <0.05,. p <0.01,. p < 0.001.
Fig. 11 is a graph of inhibition of NO release by protein kinase K, (n-3), p <0.05, p <0.01, p < 0.001.
Fig. 12 shows that ATP and LPS synergistically produced IL-1 β, (n ═ 3),. p <0.05,. p <0.01,. p < 0.001.
Fig. 13 shows that auricularia auricula lectin LAA produces IL-1 β (n-3), p <0.05, p <0.01, p <0.001 in cooperation with ATP.
Fig. 14 is a trigger condition for TNF- α release, (n-3), p <0.05, p <0.01, p < 0.001.
Fig. 15 is a graph of TNF- α release versus concentrations of auricularia auricula lectin LAA, (n-3), p <0.05, p <0.01, p < 0.001.
Fig. 16 is the effect of polymyxin B on TNF- α release, (n ═ 3),. p <0.05,. p <0.01,. p < 0.001.
Fig. 17 is a graph of DPPH clearance of auricularia auricula lectin LAA.
Fig. 18 is a graph of DPPH clearance of Vc.
FIG. 19 is a graph of ABTS clearance of Auricularia auricular lectin LAA.
Fig. 20 is a graph of ABTS clearance for Vc.
FIG. 21 shows the sequence O of Auricularia auricula lectin LAA2 -Clearance curves.
FIG. 22 shows the equation O of Vc2 -Clearance curves.
FIG. 23 is a graph showing OH radical scavenging rate of auricularia auricula lectin LAA.
FIG. 24 is a graph showing the OH radical clearance of Vc.
FIG. 25 shows the total antioxidant capacity FeSO of auricularia auricula lectin LAA4Standard graph of (2).
Detailed Description
The technical solution of the present invention is not limited to the following specific embodiments, but includes any combination of the specific embodiments.
The first embodiment is as follows: the black fungus lectin of the embodiment is prepared by the following steps:
firstly, preparing a black fungus lectin crude extract;
secondly, mixing the black fungus agglutinin crude extract with pig gastric mucin II type-cyanogen bromide activated agarose gel;
and thirdly, centrifuging, dissociating, ultrafiltering, and freeze-drying to obtain the auricularia auricula lectin LAA.
The second embodiment is as follows: the present embodiment differs from the first embodiment in that: the pig gastric mucin II type-cyanogen bromide activated agarose gel is prepared by coupling pig gastric mucin II type serving as a ligand to agarose gel (sepharose-4B). Other steps and parameters are the same as those in the first embodiment.
The third concrete implementation mode: the present embodiment is different from the first or second embodiment in that: the method comprises the following steps: adding phosphate buffer solution into Auricularia, mashing in a mashing machine to obtain viscous homogenate, freezing and centrifuging, collecting supernatant, and filtering under high pressure to obtain Auricularia lectin crude extract. The other is the same as in the first or second embodiment.
The fourth concrete implementation mode: the present embodiment is different from one of the first to third embodiments in that: the phosphate buffer concentration in step one was 10mM, pH 7.6. The others are the same as in one of the first to third embodiments.
The fifth concrete implementation mode: the present embodiment is different from one of the first to fourth embodiments in that: in the first step, the ratio of the phosphate buffer solution to the black fungus is 100mL to 5 g. The other is the same as one of the first to fourth embodiments.
The sixth specific implementation mode: the present embodiment is different from one of the first to fifth embodiments in that: in the first step, the freezing and centrifuging speed is 5000r/min, and the time is 30 min. The other is the same as one of the first to fifth embodiments.
The seventh embodiment: the present embodiment is different from one of the first to sixth embodiments in that: the supernatant collected in step one was high pressure filtered through four layers of FN15 membranes (Whatman company Filtrak FN15 chromatography cellulose membranes). The other is the same as one of the first to sixth embodiments.
The specific implementation mode is eight: the present embodiment is different from the first to seventh embodiments in that: and in the second step, the black fungus lectin crude extract is mixed with swine gastric mucin II type-cyanogen bromide activated agarose gel according to the volume ratio of 1: 1. The other is the same as one of the first to seventh embodiments.
The specific implementation method nine: the present embodiment is different from the first to eighth embodiments in that: the mixing temperature in the second step was 6 ℃. The rest is the same as the first to eighth embodiments.
The detailed implementation mode is ten: the present embodiment is different from one of the first to ninth embodiments in that: and in the second step, the mixing duration is 8-12 h. The other is the same as one of the first to ninth embodiments.
The concrete implementation mode eleven: the present embodiment is different from the first to tenth embodiments in that: centrifuging in the third step: centrifuging at 3000r/min for 5min, washing the lower-layer precipitate with PBS for three times after centrifuging, centrifuging at 3000r/min for 5min again, discarding the supernatant, adding glycine mixed liquor into the precipitate, shaking up, centrifuging at 3000r/min for 5min, taking the supernatant, adding Tris-HCl buffer solution into the supernatant, repeating the processes of adding glycine mixed liquor into the precipitate, centrifuging, taking the supernatant and adding Tris-HCl buffer solution for 2 times, and combining the supernatants added with Tris-HCl buffer solution to obtain an ultrafiltration stock solution;
wherein the glycine mixed solution is a solution with the glycine concentration of 0.1M, NaCl, the concentration of 1M and the pH value of 3.0;
wherein the concentration of the Tris-HCl buffer solution is 1M, pH 7.8.8. The rest is the same as one of the first to tenth embodiments.
The specific implementation mode twelve: this embodiment is different from the first to eleventh embodiments in that: ultrafiltration in the third step: the 5kDa ultrafiltration desalination of the ultrafiltration stock solution is carried out, and then the concentrated solution is ultrafiltered by a 10kDa ultrafiltration centrifugal tube 4400 r/min. The rest is the same as in one of the first to eleventh embodiments.
The specific implementation mode is thirteen: the present embodiment is different from the first to twelfth embodiments in that: in the ultrafiltration process, water is added for desalting for 3 times. The rest is the same as the first to twelfth embodiments.
The specific implementation mode is fourteen: the present embodiment is different from one of the first to thirteenth embodiments in that: and (4) ultrafiltering a 10kDa ultrafiltration centrifugal tube 4400r/min to obtain a concentrated solution 1/4 in volume. The rest is the same as one of the first to the thirteenth embodiments.
Example 1
The black fungus agglutinin is prepared by the following steps:
firstly, adding a phosphate buffer solution with the concentration of 10mM and the pH value of 7.6 into black fungus, stirring in a pounding machine until the black fungus is viscous and homogenate, then freezing and centrifuging, wherein the centrifugal speed is 5000r/min, the centrifugal time is 30min, collecting supernate, and filtering the supernate with four layers of FN15 membranes under high pressure, wherein the filtrate is a black fungus agglutinin crude extract; wherein the proportion of the phosphate buffer solution to the black fungus is 100mL to 5 g;
mixing the black fungus agglutinin crude extract with porcine gastric mucin II-cyanogen bromide activated agarose gel at 6 ℃ for 8-12 h, wherein the black fungus agglutinin crude extract is mixed with the porcine gastric mucin II-cyanogen bromide activated agarose gel according to the volume ratio of 1: 1;
centrifuging at 3000r/min for 5min, washing the lower-layer precipitate with PBS for three times after centrifuging, centrifuging at 3000r/min for 5min again, discarding the supernatant, adding glycine mixed liquor into the precipitate, shaking up, centrifuging at 3000r/min for 5min, taking the supernatant, adding Tris-HCl buffer solution into the precipitate, repeating the processes of adding glycine mixed liquor into the precipitate, centrifuging, taking the supernatant and adding Tris-HCl buffer solution for 2 times, and combining the supernatants added with Tris-HCl buffer solution to obtain an ultrafiltration stock solution;
wherein the glycine mixed solution is a solution with the glycine concentration of 0.1M, NaCl, the concentration of 1M and the pH value of 3.0;
wherein the concentration of the Tris-HCl buffer solution is 1M, pH 7.8.8;
the 5kDa ultrafiltration desalination of the ultrafiltration stock solution is performed, and then the concentrated solution is ultrafiltered by a 10kDa ultrafiltration centrifuge tube 4400r/min to obtain a concentrated solution 1/4. (ii) a Adding water to remove salt for 3 times in the ultrafiltration process; freeze drying to obtain Auricularia auricula lectin LAA.
Determining the relative molecular mass of the auricularia auricula agglutinin LAA to be 18913.22 by using MALDI-TOF/TOF; the sequence of the N-terminal of the black fungus agglutinin LAA is detected to be ITAPTTTSSAATE; the black fungus agglutinin LAA is analyzed to contain the following 4 peptide segments by protein identification and comparison with a UniProt database: QIDAERK, TNHSVVVTNDK, RLNFTAGNPFPR, VRELEQVDSMTK.
Anti-tumor experiments:
CCK-8 test: the Cell Counting Kit-8 Kit is used for detecting the proliferation of the auricularia auricula lectin inhibiting tumor cells.
The specific operation is as follows:
(1) ddH was added around 96-well plates2O to prevent evaporation of the medium, and appropriate wells were selected as sample wells and control wells in a 96-well plate, and three sets of parallel wells were provided, respectively.
(2) After trypsinizing the cells in logarithmic growth phase, the cells were blown down evenly to a density of 2.5X 10 by adding the medium4Cell suspension of one/mL, 200. mu.l of cell suspension was inoculated into each well, and then the 96-well plate was placed at 37 ℃ in 5% CO2The wet incubator of (1) for 24 hours.
(3) And taking out the 96-well plate the next day, sucking out the original culture solution, adding an equal volume of PBS solution, slightly shaking, sucking out, repeating for three times, adding 100 mu l of the auricularia auricula agglutinin LAA solution with different concentrations, adding an equal volume of culture medium containing 1 per thousand DMSO into the control well, and continuously culturing for 24, 48 or 72 hours.
(4) Adding 10 μ l CCK-8 solution into each well, incubating for 1h in incubator, and detecting OD with microplate reader450。
(5) Calculating the inhibition ratio (%) of the black fungus agglutinin to the tumor cells according to the formula
Using SPSS statistical analysis software, the median inhibitory concentration of lectin on tumor cells, i.e., IC, was calculated50。
The experimental results are as follows:
inhibiting proliferation of lung cancer cell a 549:
the experiment sets black fungus agglutinin LAA with different concentrations to carry out experiments on A549 cells, the experimental result is shown in figure 1, and the experimental result shows that compared with a negative control group, when the agglutinin concentration is 250 mug/mL, the A549 cells gradually lose the original irregular polygonal form, and are mostly in air bubble, the cell nucleuses gradually disappear and are in apoptosis trend, and the growth of the A549 cells is obviously inhibited.
The concentration of the auricularia auricula agglutinin LAA is 100-; the concentration of the auricularia auricula agglutinin LAA is 50 mug/mL, the A549 cell morphology is not greatly changed, only the cells are observed to begin to gather, the cell volume is increased, and the cells are judged to begin to generate air bubble.
Selecting 100 mu g/mL as the initial concentration of the auricularia auricula agglutinin LAA for inhibiting the proliferation of A549 cells; after being diluted by equal concentration gradient (100 mug/mL, 50 mug/mL, 25 mug/mL, 12.5 mug/mL and 6.25 mug/mL), the black fungus lectin LAA respectively acts on the A549 cells for 24h, 48h and 72h, and the increase inhibition condition of the black fungus lectin LAA after acting on the A549 cells at each concentration is shown in figure 2 through detection of a CCK-8 kit; the growth inhibition of the A549 cells is concentration-dependent and time-dependent, the proliferation inhibition degree of the A549 cells is gradually deepened along with the increase of the concentration of the auricularia auricula agglutinin LAA, the inhibition degree of the A549 cells is different when the auricularia auricula agglutinin LAA is treated at the same concentration for different time, and the inhibition rate of the auricularia auricula agglutinin LAA on the A549 cells reaches a maximum value of 74 percent when the concentration of the auricularia auricula agglutinin LAA is 100 mu g/mL and the action time is 72 hours.
Inhibiting proliferation of breast cancer cells MCF-7:
the primary screening result of the auricularia auricula-judae agglutinin LAA on the breast cancer cells is shown in figure 3, compared with the control group, the MCF-7 cell morphology under the treatment of 100-one 250 mu g/mL auricularia auricula-judae agglutinin LAA is obviously changed, the shuttle-shaped or multi-angle normal morphology disappears, the cell volume is increased and becomes round, and the adsorption force with the bottle bottom is reduced; MCF-7 cells treated by 50 mu g/mL auricularia auricula agglutinin LAA still keep the original cell shape, and the volume of the cells is increased and the cells become round respectively.
Selecting 100 mu g/mL auricularia auricula agglutinin LAA as the initial concentration during re-screening; the rescreening results are shown in FIG. 4, and Auricularia auricula agglutinin LAA is diluted in equal gradient and respectively mixed with MCF-7 cells at 37 deg.C with 5% CO2The culture box is incubated for 24h, 48h and 72h, and the results show that the proliferation of MCF-7 cells is in negative correlation with the concentration of the auricularia auricula lectin LAA, namely, the higher the concentration of the auricularia auricula is, the more obvious the MCF-7 cell proliferation is inhibited, and the higher the inhibition rate of the MCF-7 cells is over time. The concentration of the auricularia auricula agglutinin LAA is 100 mug/mL, and after incubation for 72 hours, the inhibition rate of the auricularia auricula agglutinin LAA on breast cancer cells MCF-7 is up to 78%.
Inhibiting proliferation of gastric cancer cell SGC-7901:
the primary screening result of the auricularia auricula lectin LAA on SGC-7901 cells is shown in figure 5, the control cells are mostly plum blossom-shaped and are distributed in clusters, the shapes are regular and uniform, and the outlines are clear; after the auricularia auricula agglutinin LAA is added, the SGC-7901 cells begin to bubble, and the cells gradually separate from the bottom of the bottle after being deformed into a round shape.
As shown in FIG. 6, the SGC-7901 cells showed concentration and time dependence on auricularia auricula-judae lectin, and the SGC-7901 inhibition rate was only 53% after being cultured with auricularia auricula-judae lectin LAA for 72 h.
Inhibiting the proliferation of liver cancer cell HepG-2:
in the primary screening test of the auricularia auricula lectin LAA for inhibiting HepG-2, under the treatment of 50 mu g/mL of the auricularia auricula lectin LAA (shown in figure 7), the extended form of cells begins to disappear, cytoplasm shrinks, and air bubbles gradually appear; when the concentration reaches 100 mug/mL, the original form completely disappears, the volume of all cells is increased, the number is reduced and the cells begin to separate from the bottom of the bottle, and the form and the number of HepG-2 cells under the action of subsequent concentration have no great difference.
Selecting 100 mu g/mL as the initial concentration of the auricularia auricula agglutinin LAA for inhibiting HepG-2 cell proliferation; the auricularia auricula agglutinin LAA is diluted by the same volume of concentration gradient and acts on HepG-2 cells for 24h, 48h and 72h respectively (as shown in figure 8), the inhibition rate of HepG-2 is concentration-dependent with the auricularia auricula agglutinin LAA, but the inhibition rates of HepG-2 treated by 48h and 72h agglutinin LAA are not obviously different in acting time, which shows that HepG-2 has dependency on the concentration of the auricularia auricula agglutinin LAA within 48h, and the maximum inhibition rate of the auricularia auricula agglutinin LAA on HepG-2 cells reaches 80%.
Immunoregulation experiment
Cell treatment:
(1) ddH was added around 96-well plates2O to prevent evaporation of the medium, and appropriate wells were selected as sample wells and control wells in a 96-well plate, and three sets of parallel wells were provided, respectively.
(2) After trypsinizing the cells in logarithmic growth phase, the cells were blown down evenly to a density of 2.5X 10 by adding the medium4Cell suspension of one/mL, 200. mu.l of cell suspension was inoculated into each well, and then the 96-well plate was placed at 37 ℃ in 5% CO2The wet incubator of (1) for 24 hours.
(3) And taking out the 96-well plate the next day, sucking out the original culture solution, adding PBS solution with the same volume, slightly shaking, sucking out, repeating for three times, adding 100 mu l of the auricularia auricula agglutinin LAA solution with different concentrations, culturing for 24h, and collecting the culture solution, namely the sample solution to be detected.
Enzyme-linked immunosorbent assay:
(1) according to the specification, 10 Xcoating Buffer is diluted to 1 Xcoating Buffer, 5 XELISA/ELISPOT is diluted to 1 XELISA/ELISPOT, and Capture Antibody and Detection Antibody are prepared respectively by using the two dilutions for standby.
(2) The standard is injected with 1mL ddH2O, preparing a standard solution with the concentration of 15ng/mL, taking 100 mu l of the standard solution, and diluting the standard solution by 1 XELISA/ELISPOT diluent to obtain the final concentration of 1000 pg/mL.
(3) Avidin-labeled horseradish peroxidase solution was prepared for use in 1 × ELISA/ELISPOT dilutions.
(4) Mu.l of Capture Antibody was added to each well of the ELISA plate 9018, and the 96-well plate was sealed with a preservative film and cultured overnight at 2-8 ℃.
(5) Adding 250 mul of washing buffer (1 XPBS, 0.05% Tween-20) into each well of a 96-well plate, soaking for 1-2 min, then discarding, repeating the process for at least 3 times, and sucking the residual washing liquid by using a filter paper strip.
(6) 200. mu.l of 1 × ELISA/ELISPOT dilution was added to each well and incubated at room temperature for 1 h.
(7) And (5) repeating the step.
(8) Add 100. mu.l of standard solution to the first well of 96-well plate, dilute to the eighth well in a continuous 2-fold gradient, add 100. mu.l of sample solution to be tested (containing Auricularia auricular lectin LAA) to the appropriate well, set 3 biological replicates, and add 100. mu.l of 1 × ELISA/ELISPOT diluent as blank control.
(9) And (5) repeating the step.
(10) Mu.l of Detection Antibody was added to the corresponding wells and incubated for 1h at room temperature with plastic wrap sealing.
(11) And (5) repeating the step.
(12) Mu.l of Avidin-HRP was added to the corresponding well of the 96-well plate and incubated for 30min at sealed room temperature.
(13) And (5) repeating the step.
(14) Mu.l of 1 XTMB solution was added to the corresponding well of the 96-well plate and incubated for 15min at room temperature.
(15) Mu.l of stop buffer (1M H3PO4) was added to each well.
(16) The absorbance of the standard and sample was measured at 450nm using a microplate reader.
Griiss test:
cell treatment:
(1) ddH was added around 96-well plates2O to prevent evaporation of the medium, and appropriate wells were selected as sample wells and control wells in a 96-well plate, and three sets of parallel wells were provided, respectively.
(2) After trypsinizing the cells in logarithmic growth phase, the cells were blown down evenly to a density of 2.5X 10 by adding the medium4Cell suspension of one/mL, 200. mu.l of cell suspension was inoculated into each well, and then the 96-well plate was placed at 37 ℃ in 5% CO2The wet incubator of (1) for 24 hours.
(3) And taking out the 96-well plate the next day, sucking out the original culture solution, adding PBS solution with the same volume, slightly shaking, sucking out, repeating for three times, adding 100 mu l of the auricularia auricula agglutinin LAA solution with different concentrations, culturing for 24h, and collecting the culture solution, namely the sample solution to be detected.
According to the Griess method, the content of NO released by mouse macrophages is detected. Because NO is easily oxidized into NO in vivo or in aqueous solution2 -And in an acidic environment, NO2 -The diazo compound is easy to react with diazo sulfanilamide to generate the diazo compound, and then the diazo compound and naphthyl ethylene diamine are subjected to coupling reaction. According to the concentration of the product formed and NO2 -The NO content is calculated from the linear relationship of (1). The detailed steps are as follows:
(1) 10mM NaNO was prepared2A standard stock solution; the stock solution was diluted 10-fold before the experiment as the initial concentration solution and continuously diluted with an equal gradient for determination of the NO standard curve.
(2) And (4) preparing a Griess reagent.
Solution A: 1.0g of anhydrous sulfanilic acid, adding 70mL of deionized water, heating to fully dissolve the sulfanilic acid, adding 6mL of 85% concentrated sulfuric acid, and fixing the volume to 100 mL.
And B, liquid B: 0.1g of N-1-naphthyl ethylenediamine hydrochloride is dissolved in deionized water, and the volume is fixed to 100 mL.
(3) 50 μ l of NaNO was added to each concentration in a 96-well plate2Taking another blank hole, adding 50 μ l of sample solution (containing auricularia auricula agglutinin LAA with different concentrations) to be tested, and repeating the parallel test for three times.
(4) Adding 50 mu l A solution into each well, and incubating for 10min in an incubator at 37 ℃; and taking out the 96-well plate, adding 50 mu l of the solution B into each well, mixing uniformly, and then continuously incubating in an incubator at 37 ℃ for 10 min.
(5) And (4) taking out the 96-well plate, slightly oscillating for several times to avoid bubbles, and detecting the OD value of the corresponding well at the wavelength of 540nm of the microplate reader.
(6) And drawing an NO standard curve according to the measurement result, and calculating the NO content released by the mouse macrophage under different treatments according to the standard curve.
The experimental results are as follows:
the auricularia auricula lectin LAA induces NO generation, mouse mononuclear macrophage J774A.1 is selected as an immunocompetence test material, and the cell is derived from female mouse abdominal sarcoma cells, so that an immune response reaction under the stimulation of the auricularia auricula lectin LAA can be better reflected, and reliable data support is provided for test results.
The method for detecting the release amount of NO in Jew's ear agglutinin LAA acting J774A.1 cells by using a Grignard method is shown in figure 9, the release amount of NO and the concentration of Jew's ear agglutinin LAA are in a linear dependence relationship (figure 9), namely, the NO generated and released by induced macrophages is gradually increased along with the increase of the concentration of the Jew's ear agglutinin LAA, and the release of NO is verified to be LPS-independent. The elimination of errors caused by false positive results is particularly important because the materials are often subjected to false positive results caused by LPS (lipopolysaccharide) pollution in the test process, so that the test results are inaccurate. LPS is the main component of gram-negative bacteria cell wall, the heat resistance is strong, the activity is still maintained after heating in boiling water for 10min, but the black fungus lectin LAA is denatured under high temperature treatment, the biological function is lost, the release amount of NO is reduced (figure 10), the black fungus lectin is laterally verified to be free of LPS pollution, and the accuracy of the test result is ensured. Protein kinase K is a protein inhibitor, can effectively hydrolyze protein into amino acid, loses complex structure and protein function, and has the advantages that the NO release amount of the black fungus lectin LAA is remarkably reduced under the action of the protein kinase K (figure 11), and LPS (low pressure lipoprotein lipase) under the action of the protein kinase has NO phenomenon of reducing the NO release amount, so that the protein kinase K is a good lectin inhibitor and can inhibit the immunoregulation level.
Auricularia auricula agglutinin LAA induces interleukin IL-1 β production
FIG. 12 shows that the content of interleukin IL-1 β produced by macrophage of mice is tested by applying ELISA method, when ATP or LPS is added into the culture medium alone, IL-1 β is hardly released, and after ATP and LPS are added simultaneously, the result of observation shows that the release amount of IL-1 β is increased significantly, which indicates that the release of IL-1 β requires the synergistic stimulation of ATP and LPS. FIG. 13 shows that the release amount of IL-1 β is almost the same when the Auricularia auricula lectin LAA is added into the culture medium alone, and the release amount of IL-1 β is obviously increased after 24h of culture when the Auricularia auricula lectin LAA and the ATP are added into the macrophage simultaneously, and the difference is significant compared with the control group, which indicates that the Auricularia auricula lectin LAA can exist similarly to the LPS and synergistically regulate the immunological activity of organisms with the ATP.
Auricularia auricula agglutinin LAA induces tumor necrosis factor TNF- α production
ELISA detects that Jew ear agglutinin LAA stimulates J774A.1 cells to generate TNF- α as shown in figures 14-16, ATP is added into a reaction system, no TNF- α is released, after LPS is added into a culture medium, the release amount of TNF- α is obviously increased, and LPS and ATP are simultaneously added, the detected release amount is not different from the release amount of TNF- α when LPS is independently added (figure 14), the release amount of TNF- α is only related to stimulation of LPS, the result of figure 15 shows that the release amount of TNF- α is concentration-dependent to the Jew ear agglutinin LAA, polymyxin PMB is a good endotoxin inhibitor, and the result of figure 16 shows that the release amount of the Jew ear agglutinin LAA TNF- α added with PMB is not significantly different from the release amount of TNF- α not added with PMB, and is obviously reduced after the release amount of macrophage treated by LPS alone is added into the culture medium, thereby verifying the reliability of a test sample.
Oxidation resistance test
DPPH free radical scavenging assay:
(1) the DPPH powder was dissolved in methanol to prepare a 6mmol/L DPPH stock solution, which was stored at-20 ℃ for further use, diluted 100-fold with methanol, i.e., 60. mu. mol/L.
(2) Adding Auricularia auricula agglutinin LAA solution with different concentrations into 1.5mL EP tube, adding 50 μ L into cuvette, taking 50 μ L DMSO as reference solution, adding 3mL 60 μmol/L DPPH methanol solution respectively, shaking gently, and standing at room temperature in dark for 30 min.
(3) And (3) measuring the light absorption value of each solution at the wavelength of 515nm by using a spectrophotometer, zeroing by using an equal volume of methanol solution before measurement, and calculating the free radical clearance of the sample solution to be measured according to the following formula.
Wherein As is the absorbance value of the sample tube, A0The absorbance value of the reference tube is used.
The experimental results are as follows: auricularia auricula agglutinin LAA is selected for DPPH free radical scavenging test, and IC is used50The value is used for measuring the strength of the antioxidant capacity of the tea. The DPPH clearance curves of various concentrations (6.25. mu.g/mL, 12.5. mu.g/mL, 25. mu.g/mL, 50. mu.g/mL, 100. mu.g/mL) of auricularia auricula lectin LAA and DPPH clearance curves of various concentrations (0.00625. mu.g/mL, 0.0125. mu.g/mL, 0.025. mu.g/mL, 0.50. mu.g/mL, 0.1. mu.g/mL) of Vc are shown in FIGS. 17 and 18, and it can be seen that the clearance rate of the auricularia auricula lectin LAA on DPPH free radicals is obviously lower than that under the action of Vc, and the result shows that the clearance rate of the auricularia auricula lectin LAA on DPPH is general.
EC of Auricularia auricula lectin LAA on DPPH50EC of 91.44 + -4.20 μ g/mL, and Vc vs DPPH of control group50Value comparison, difference and significance (P)<0.001), indicating that the auricularia auricula lectin LAA has poor DPPH clearance rate and cannot effectively clear DPPH.
TABLE 1 elimination of DPPH
Mean±SD,n=3,*p<0.05,versus control.
ABTS free radical scavenging assay:
ABTS is easily oxidized into green ABTS under the action of oxidant·+ABTS in the presence of antioxidants·+Can be inhibited, and can be measured at 734nm for ABTS·+The antioxidant capacity of the sample is calculated from the absorbance of (b).
(1)ABTS·+Preparing a stock solution: 5mmol/L ABTS solution is prepared by PBS, mixed with 140nmol/L potassium persulfate, diluted by PBS to the light absorption value of 0.70 +/-0.02 at 734nm, kept stand and protected from light at-20 ℃ for standby.
(2) Adding 100 μ l of Auricularia auricula agglutinin LAA solution with different concentrations into cuvette, adding 3mL of ABTS + stock solution into 100 μ l of DMSO as reference solution, shaking, and standing at room temperature in dark for 10 min.
(3) The solution was zeroed with an equal volume of PBS, and then the absorbance of each solution at 734n was measured, and the radical clearance of the sample solution to be measured (black fungus agglutinin LAA solution) was calculated according to the following formula.
Wherein As is the absorbance value of the sample tube, A0The absorbance value of the reference tube is used.
The experimental results are as follows: the clearance rate of auricularia auricula lectin LAA on ABTS is shown in figure 19, and the result shows that the clearance rate of auricularia auricula lectin LAA on ABTS is gradually enhanced along with the increase of the concentration of auricularia auricula lectin, and certain concentration dependence is shown.
EC of black fungus agglutinin LAA on ABTS50The value is 45.70 +/-0.11 mu g/mL, and the EC of the control group Vc on ABTS50The values are not obvious in difference, so that the black fungus lectin LAA has the capability of clearing ABTS, can be used as an antioxidant to prevent organisms from being oxidized by ABTS, and accordingly related diseases and adverse symptoms are avoided.
TABLE 2 pairs of ABTS+EC of (1)50Value of
Mean±SD,n=3,*p<0.05,versus control.
Superoxide anion radical scavenging test
Pyrogallol, also known as pyrogallic acid, is easily autoxidized under alkaline conditions to release superoxide anions, and the occurrence of the superoxide anions accelerates the oxidation of the pyrogallol. The addition of the antioxidant can block the production of superoxide anion, thereby reducing the autoxidation rate of pyrogallol, and the ability to scavenge superoxide anion is calculated by comparing the autoxidation rates before and after the addition of the antioxidant.
Determination of the rate of auto-oxidation of pyrogallol: 4.5mL Tris-HCl solution pH8.2 with 4.2mL ddH2Mixing O, incubating at 25 deg.C for 30min, and rapidly adding 0.3Slightly oscillating and mixing the solution of the pyrogallol mL, recording the change of absorbance at 320nm within 5min, drawing a time (t) -absorbance (A) curve, and calculating the autoxidation rate (V) of the pyrogallol0)。
And (3) determining the autoxidation rate of pyrogallol under the action of the black fungus agglutinin LAA to be detected: 4.5mL Tris-HCl solution and 3.3mL ddH2Mixing O, incubating at 25 deg.C for 30min, rapidly adding 0.9mL LAA gradient dilution solution of Auricularia auricula agglutinin and 0.3mL pyrogallol solution, shaking gently, mixing, recording absorbance change at 320nm within 5min, drawing time (t) -absorbance (A) curve, and calculating auto-oxidation rate (V) of pyrogallol under the action of test substance1). The following formula:
the experimental results are as follows: auricularia auricula agglutinin LAA to superoxide anion (O)2 -) The scavenging condition of (A) is shown in FIG. 21, and superoxide anion (. O) is visible2 -) The clearance rate of the lectin-containing bioactive peptide is in direct linear correlation with the concentration of the lectin, has concentration dependence and has good antioxidant capacity.
Auricularia auricula agglutinin LAA to superoxide anion (O)2 -) EC of the cleaning ability of50The value is 35.03 +/-1.24 mu g/mL, and the statistical analysis result shows that the EC of the product is50The value is not different from the control group, which indicates that the auricularia auricula agglutinin LAA has better superoxide anion (O)2 -) The ability of the cell to perform.
TABLE 3 Pair.O2 -EC of (1)50Value of
Mean±SD,n=3,*p<0.05,versus control.
Hydroxyl radical scavenging test:
under the condition of ferrous ions, hydrogen peroxide is easily reduced into hydroxyl radicals, and the hydroxyl radicals can be captured by adding salicylic acid to generate characteristic absorption at the wavelength of 510 nm. When an antioxidant is added into the reaction system, the ability of salicylic acid for capturing hydroxyl radicals is hindered, and further the light absorption value at a specific wavelength is reduced, so that the antioxidant ability of the substance to be tested is evaluated.
Uniformly mixing 100 mu L of to-be-detected auricularia auricula agglutinin LAA gradient diluted solution, 100 mu L of 9mmol/L ferrous sulfate solution and 100 mu L of 10mmol/L hydrogen peroxide solution, incubating in an oven at 37 ℃ for 20min, rapidly adding an isovolumetric 9mmol/L salicylic acid solution, gently mixing, continuing to incubate in the oven at 37 ℃ for 30min, and detecting the light absorption value at 510nm, ddH, by using a spectrophotometer2And O is used as a blank control group, and the hydroxyl radical clearance rate of the sample to be detected is calculated according to the following formula:
the removal of OH free radicals by auricularia auricula lectin LAA is shown in FIG. 23, and it can be seen that the removal rate of OH free radicals is in direct proportion to the concentration of lectin, has concentration dependence, has certain antioxidant capacity, and is lower than the control group Vc in the removal capacity of OH free radicals (shown in FIG. 24).
EC of auricularia auricula agglutinin LAA on OH free radical scavenging capacity50A value of 28.20. + -. 0.74. mu.g/mL, and its EC, as statistically analyzed50The value is not obviously different from the control group, which shows that the auricularia auricula agglutinin LAA has better capability of eliminating OH free radicals.
TABLE 4 EC for OH50Value of
Mean±SD,n=3,*p<0.05,versus control.
Determination of total antioxidant capacity:
iron ion reducing power (FRAP) means that an antioxidant can reduce Fe in an acidic environment3+Reduction of TPTZ to Fe2 +TPTZ, whereby the change is detected at a wavelength of 593nm, in order to react with the test substanceTotal antioxidant capacity.
Preparing an FRAP working solution: 2.5mL of 300mmol/L acetate solution, 0.25mL of 10mmol/L TPTZ solution and 0.25mL of 20mmol/L ferric chloride solution.
FeSO4Drawing a standard curve: 10 mul of FeSO with each equal concentration gradient is respectively taken4And (3) uniformly mixing the standard solution and 100 mul of FRAP working solution, reacting at room temperature for 30min, measuring the light absorption value of 593nm by using an enzyme-labeling instrument, and drawing a standard curve according to the light absorption value.
Antioxidant activity of the sample: collecting 1mg Auricularia auricula agglutinin LAA, preparing into 10mg/mL solution with PBS, mixing 10 μ l and 100 μ l FRAP working solution at room temperature, reacting for 30min, and measuring light absorption value at 593nm to obtain FeSO with same light absorption value4The concentration of (c) represents the total antioxidant capacity of the sample.
The experimental results are as follows: the standard curve of ferrous sulfate is shown in figure 25, and a linear regression equation is obtained: 0.5634X +0.0006 for Y, correlation coefficient squared R2The linear relation is good when the Fe content is 0.9993, and the Fe content can be used for subsequent reduction2+And (4) detecting the concentration. Detection of Fe in Auricularia auricula lectin3+In the test of reducing power, FeSO with the same light absorption value is obtained4The iron ion reduction oxidation resistance is shown, and the result shows that the FRAP value of the black fungus agglutinin is 24.53 +/-1.60, has no obvious difference with a control group, and has good total oxidation resistance.
TABLE 5 Total antioxidant capacity
Mean±SD,n=3,*p<0.05,versus control
The black fungus agglutinin LAA inhibits the proliferation of lung cancer cells A549, breast cancer cells MCF-7, gastric cancer cells SGC-7901 and liver cancer cells HepG2, and is time-concentration dependent, and IC detected after the agglutinin acts for 72 hours5028.19 +/-1.92 mu g/mL, 30.33 +/-1.38 mu g/mL, 61.87 +/-3.76 mu g/mL and 28.79 +/-0.74 mu g/mL in sequence, the auricularia auricula agglutinin LAA promotes mouse macrophage J774A.1 to release NO, IL-1 β and TNF- α, and can improve the activity of immunity.Auricularia auricula agglutinin LAA can scavenge DPPH free radical (DPPH. cndot.) and ABTS free radical (ABTS)+) Hydroxyl radical (. OH) and superoxide anion (. O)2 -) EC of (1)50The values are 91.44 +/-4.20 mu g/mL, 45.70 +/-0.11 mu g/mL, 28.20 +/-0.74 mu g/mL and 35.03 +/-1.24 mu g/mL respectively, the auricularia auricula agglutinin LAA except DPPH has better effect of eliminating other three free radicals, the FRAP value is 24.53 +/-1.60, and the antioxidation effect is better.
Although the invention has been described above by way of general illustration and specific embodiments, it is within the scope of the invention as claimed that modifications and improvements may be made thereto without departing from the spirit of the invention.
Claims (7)
1. A preparation method of black fungus agglutinin is characterized in that the black fungus agglutinin is prepared by the following steps:
firstly, preparing a black fungus lectin crude extract;
secondly, mixing the black fungus agglutinin crude extract with pig gastric mucin II type-cyanogen bromide activated agarose gel;
and thirdly, centrifuging, dissociating, ultrafiltering, and freeze-drying to obtain the auricularia auricula lectin LAA.
2. The method according to claim 1, wherein the porcine gastric mucin type II-cyanogen bromide activated Sepharose is prepared by coupling porcine gastric mucin type II as ligand to Sepharose.
3. The method for preparing black fungus lectin according to claim 1, characterized by comprising the following steps: adding phosphate buffer solution into Auricularia, mashing in a mashing machine to obtain viscous homogenate, freezing and centrifuging, collecting supernatant, and filtering under high pressure to obtain Auricularia lectin crude extract.
4. The method according to claim 1, wherein the crude extract of Auricularia auricula lectin obtained in step two is mixed with porcine gastric mucin type II-cyanogen bromide activated Sepharose at a volume ratio of 1: 1.
5. The method for preparing black fungus lectin as claimed in claim 1, wherein centrifugation is performed in step three: centrifuging at 3000r/min for 5min, washing the lower-layer precipitate with PBS for three times after centrifuging, centrifuging at 3000r/min for 5min again, discarding the supernatant, adding glycine mixed liquor into the precipitate, shaking up, centrifuging at 3000r/min for 5min, taking the supernatant, adding Tris-HCl buffer solution into the supernatant, repeating the processes of adding glycine mixed liquor into the precipitate, centrifuging, taking the supernatant and adding Tris-HCl buffer solution for 2 times, and combining the supernatants added with Tris-HCl buffer solution to obtain an ultrafiltration stock solution;
wherein the glycine mixed solution is a solution with the glycine concentration of 0.1M, NaCl, the concentration of 1M and the pH value of 3.0;
wherein the concentration of the Tris-HCl buffer solution is 1M, pH 7.8.8.
6. The method for preparing black fungus lectin as claimed in claim 5, wherein ultrafiltration is performed in step three: the 5kDa ultrafiltration desalination of the ultrafiltration stock solution is carried out, and then the concentrated solution is ultrafiltered by a 10kDa ultrafiltration centrifugal tube 4400 r/min.
7. An auricularia auricula lectin, characterized in that it is obtained by the process according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010031547.3A CN111217893A (en) | 2020-01-13 | 2020-01-13 | Black fungus agglutinin and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010031547.3A CN111217893A (en) | 2020-01-13 | 2020-01-13 | Black fungus agglutinin and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111217893A true CN111217893A (en) | 2020-06-02 |
Family
ID=70831125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010031547.3A Pending CN111217893A (en) | 2020-01-13 | 2020-01-13 | Black fungus agglutinin and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111217893A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112961228A (en) * | 2021-04-27 | 2021-06-15 | 黑龙江大学 | Method for extracting black fungus agglutinin |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6084072A (en) * | 1990-04-11 | 2000-07-04 | The Regents Of The University Of Michigan | Purified lectin and methods of use |
JP2003073398A (en) * | 2001-09-03 | 2003-03-12 | Yukiguni Maitake Co Ltd | Grifola frondosa-derived lectin and purification method for the same |
CN101240037A (en) * | 2008-03-12 | 2008-08-13 | 黑龙江大学 | Jelly fungi heptasaccharide and its preparation technique and application |
CN104480090A (en) * | 2014-11-28 | 2015-04-01 | 四川德博尔制药有限公司 | Preparation method of porcine pepsin and gastric mucin |
TW201841935A (en) * | 2017-04-11 | 2018-12-01 | 國立研究開發法人產業技術總合研究所 | Method of lectin immobilization |
CN112961228A (en) * | 2021-04-27 | 2021-06-15 | 黑龙江大学 | Method for extracting black fungus agglutinin |
-
2020
- 2020-01-13 CN CN202010031547.3A patent/CN111217893A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6084072A (en) * | 1990-04-11 | 2000-07-04 | The Regents Of The University Of Michigan | Purified lectin and methods of use |
JP2003073398A (en) * | 2001-09-03 | 2003-03-12 | Yukiguni Maitake Co Ltd | Grifola frondosa-derived lectin and purification method for the same |
CN101240037A (en) * | 2008-03-12 | 2008-08-13 | 黑龙江大学 | Jelly fungi heptasaccharide and its preparation technique and application |
CN104480090A (en) * | 2014-11-28 | 2015-04-01 | 四川德博尔制药有限公司 | Preparation method of porcine pepsin and gastric mucin |
TW201841935A (en) * | 2017-04-11 | 2018-12-01 | 國立研究開發法人產業技術總合研究所 | Method of lectin immobilization |
CN112961228A (en) * | 2021-04-27 | 2021-06-15 | 黑龙江大学 | Method for extracting black fungus agglutinin |
Non-Patent Citations (4)
Title |
---|
RAM SARUP SINGH等: "Purification and characterization of a novel thermostable mycelial lectin from Aspergillus terricola", 《APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY》 * |
刘振东等: "西藏黑木耳中 1 种新的凝集素的分离纯化及鉴定", 《中草药》 * |
曾仲奎等: "野花生豆凝集素的纯化和性质", 《生物化学杂志》 * |
马成瑶等: "黑木耳凝集素的分离、纯化及抗肿瘤活性研究", 《黑龙江大学自然科学学报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112961228A (en) * | 2021-04-27 | 2021-06-15 | 黑龙江大学 | Method for extracting black fungus agglutinin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Liu et al. | Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model | |
Wong et al. | Influence of drying treatment on three Sargassum species 2. Protein extractability, in vitro protein digestibility and amino acid profile of protein concentrates | |
CN106434804B (en) | A kind of protein peptides with antioxidation activity and preparation method thereof | |
Bao et al. | Effect of sulfated modification on the molecular characteristics and biological activities of polysaccharides from Hypsizigus marmoreus | |
Huang et al. | Antioxidant and antiproliferative activities of polysaccharide fractions from litchi pulp | |
Pan et al. | Ultrasound-assisted deep eutectic solvents extraction of polysaccharides from Morchella importuna: optimization, physicochemical properties, and bioactivities | |
CN111217893A (en) | Black fungus agglutinin and preparation method thereof | |
Guo et al. | Hot water extract of the sclerotium of Polyporus rhinocerus Cooke enhances the immune functions of murine macrophages | |
Cai et al. | Changes in bioactive compounds and their relationship to antioxidant activity in white sufu during manufacturing | |
Zhang et al. | Isolation and evaluation of two angiotensin-I-converting enzyme inhibitory peptides from fermented grains (Jiupei) used in Chinese Baijiu production | |
Agbaje et al. | Organic macromolecules in shells of Arctica islandica: comparison with nacroprismatic bivalve shells | |
CN104530187A (en) | Saury antioxidative peptide as well as separation and extraction method and application thereof | |
Yan et al. | Anti-glycated and antiradical activities in vitro of polysaccharides from Ganoderma capense | |
Chen et al. | Molecular weight affected antioxidant, hypoglycemic and hypotensive activities of cold water extract from Pleurotus citrinopileatus | |
CN110627896A (en) | Calcium chelating peptide and preparation method and application thereof | |
Dai et al. | Extraction optimization, preliminary characterization and antioxidant activity of glycoproteins from the muscle of Sepia pharaonis | |
CN116751251A (en) | Two polypeptides with alpha-glucosidase inhibitory activity and application thereof | |
JP5705264B2 (en) | Silver ear polysaccharide for retinal cell protection and method for producing the same | |
Macáková et al. | Free-radical scavenging activity of some European Polyporales | |
CN109486886A (en) | A kind of maize oligopeptide selenium and its preparation method and application | |
CN108753897A (en) | A kind of preparation method of sea cucumber internal organ polypeptide | |
CN115960165A (en) | Selenium-rich ACE inhibitory peptide derived from moringa oleifera leaves and application thereof | |
KR100468649B1 (en) | Anti-complementary biopolymer from fruiting body of Coriolus versicolor and method for isolation thereof | |
CN107519217B (en) | High-antioxidation anticancer composition containing donkey-hide gelatin hydrolysate and ginkgo leaf extract as well as preparation method and application thereof | |
WO2020134772A1 (en) | β-LACTOGLOBULIN-VITAMIN CONJUGATE COMPRISING SUGAR ALCOHOLS AND PREPARATION METHOD THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200602 |